Home › Funds › Opaleye Management Inc. › URGN
Opaleye Management Inc. position in URGN
UROGEN PHARMA LTD · Health Care
Opaleye Management Inc. reported holding 1,439,996 shares of URGN (UROGEN PHARMA LTD) in its Q2 2026 13F filing — a position valued at US$53.0M, representing 4.80% of its reported portfolio and ranking #5 among its reported holdings. Opaleye Management Inc. has disclosed URGN holdings in 9 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Opaleye Management Inc.'s URGN position evolved
Opaleye Management Inc. first disclosed a stake in URGN in Q3 2023 at 320,000 shares (US$4.5M). The position peaked in Q2 2026 at 1,439,996 shares, worth US$53.0M. Across 9 filings, Opaleye Management Inc. increased the stake 3 time(s), trimmed it 3 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 1,439,996 shares valued at US$53.0M — an increase of 9,996 shares quarter over quarter.. Notable position changes include a 53% increase in Q2 2024 (shares fell 24% over the following quarter), a 46% trim in Q4 2024 (shares rose 4% over the following quarter), a 433% increase in Q1 2026 (shares rose 105% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 320.00K | $4.48M | New |
| Q4 2023 | 320.00K | $4.80M | Hold |
| Q1 2024 | 270.00K | $4.05M | Reduce |
| Q2 2024 | 412.00K | $6.91M | Add |
| Q3 2024 | 404.10K | $5.13M | Reduce |
| Q4 2024 | 220.00K | $2.34M | Reduce |
| Q4 2025 | 268.42K | $6.29M | New |
| Q1 2026 | 1.43M | $25.71M | Add |
| Q2 2026 | 1.44M | $52.99M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About URGN and 13F data
URGN (UROGEN PHARMA LTD) is a Health Care company. 39 other funds we track also report a position in URGN — the largest reported positions include RTW INVESTMENTS, LP (US$167.2M), Kynam Capital Management, LP (US$89.6M), Jefferies Financial Group Inc. (US$80.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding URGN
- RTW INVESTMENTS, LP 4.54M sh · $167.22M · Q2 2026
- Kynam Capital Management, LP 2.43M sh · $89.58M · Q2 2026
- Jefferies Financial Group Inc. 2.20M sh · $80.95M · Q2 2026
- ACORN CAPITAL ADVISORS, LLC 1.67M sh · $61.58M · Q2 2026
- SILVERARC CAPITAL MANAGEMENT, LLC 1.30M sh · $47.91M · Q2 2026
- MPM BioImpact LLC 933.41K sh · $34.35M · Q2 2026
- Soleus Capital Management, L.P. 829.81K sh · $30.54M · Q2 2026
- Boxer Capital Management, LLC 500.00K sh · $18.40M · Q2 2026
- Privium Fund Management B.V. 210.00K sh · $7.73M · Q2 2026
- SUPERSTRING CAPITAL MANAGEMENT LP 191.31K sh · $7.04M · Q2 2026
More on Opaleye Management Inc.
FAQ
How long has Opaleye Management Inc. held URGN?
Opaleye Management Inc. has disclosed URGN holdings in 9 of the last 12 reported quarters, going back to Q3 2023.
What is Opaleye Management Inc.'s current position in URGN?
As of Q2 2026, Opaleye Management Inc. holds 1.44M shares of URGN (UROGEN PHARMA LTD), valued at $52.99M, representing 4.80% of its reported portfolio and ranking #5.
Has Opaleye Management Inc. been buying or selling URGN?
In the latest 13F filing (Q2 2026), Opaleye Management Inc. increased its position in URGN. The position peaked in Q2 2026 at 1.44M shares.
Which other funds hold URGN?
Other major institutional holders of URGN include RTW INVESTMENTS, LP, Kynam Capital Management, LP, Jefferies Financial Group Inc., among 39 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.